RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) saw a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 1,131,607 shares, an increase of 67.8% from the May 14th total of 674,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
RemeGen Stock Performance
REGMF stock remained flat at $9.50 during midday trading on Monday. RemeGen has a 12 month low of $9.50 and a 12 month high of $15.91. The company’s fifty day simple moving average is $11.23 and its 200 day simple moving average is $10.57.
About RemeGen
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
See Also
- Five stocks we like better than RemeGen
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
